Posted by Michael Wonder on 05 Jul 2017
NICE terminates another three cancer medicine assessments
5 July 2017 - This brings the number of terminated assessments for 2017 to nine.
The new terminated assessments are:
- Ibrutinib for untreated chronic lymphocytic leukaemia without a 17p deletion or TP53 mutation
- Daratumumab with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma
- Bortezomib for treating multiple myeloma after second or subsequent relapse
All three medicines are sponsored by Janssen-Cilag.
Read NICE statement for ibrutinib
